Natera
Trade Natera 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About NTRA
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).
NTRA Key Statistics
Stock Snapshot
The current Natera(NTRA) stock price is $196.97, with a market capitalization of 27.25B. The stock trades at a price-to-earnings (P/E) ratio of -94.61.
On 2026-02-27, Natera(NTRA) stock traded between a low of $196.22 and a high of $212.50. Shares are currently priced at $196.97, which is +0.4% above the low and -7.3% below the high.
Natera(NTRA) shares are trading with a volume of 876.83K, against a daily average of 912.74K.
In the last year, Natera(NTRA) shares hit a 52-week high of $256.36 and a 52-week low of $125.38.
In the last year, Natera(NTRA) shares hit a 52-week high of $256.36 and a 52-week low of $125.38.
NTRA News
Analyst Kyle Mikson CFA of Canaccord Genuity maintained a Buy rating on Natera, retaining the price target of $285.00. Claim 50% Off TipRanks Premium Unlock hed...
Natera (NTRA) will present new data in genitourinary malignancies at the American Society of Clinical Oncology Genitourinary Cancers Symposium, taking place Feb...
Evercore ISI raised the firm’s price target on Natera (NTRA) to $260 from $250 and keeps an Outperform rating on the shares. Published first on TheFly – the ul...
Analyst ratings
87%
of 23 ratingsMore NTRA News
If you are wondering whether Natera's current share price reflects its real value, you are not alone. This article will help you frame that question clearly. N...
Daniel Brennan, an analyst from TD Cowen, maintained the Buy rating on Natera. The associated price target remains the same with $280.00. Daniel Brennan has gi...
AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...
Reports Q4 revenue $665.M, consensus $600.7M. Reports Q4: Product revenues grew 39.8% over the same period. Generated a gross margin1 of 66.9% in the fourth qua...
Natera (NTRA) announced results from the SINERGY trial, a Phase 2 study in recurrent or metastatic head and neck squamous cell carcinoma. Data was recently pres...
Natera recently attracted positive attention after Duquesne Family Office highlighted the company’s strong oncology testing momentum, including 54% growth in th...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.